Selectively deglycosylated human immunodeficiency virus type 1 e

Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

4241301, 4241391, 4242081, 4241411, 4241421, 4241471, 4241481, 530395, 5303875, 5303879, 53038835, A61K 3921, A61K 39395, A61K 3942, A61K 3940

Patent

active

061032387

ABSTRACT:
Selective deglycosylation of HIV-1 envelope proteins enhances their ability to elicit a protective immune response in people. Glycosylation can reduce or prevent immunological recognition of envelope protein domains. Selective deglycosylation exposes these domains and improves the opportunity for a protective immune response. Deglycosylation which produces substantial conformational changes (as determined by loss of infectivity) should be avoided. Recombinant HIV-1 envelope glycoproteins are generated which have primary amino acid sequence mutation(s) in consensus sequence(s) for N-linked glycosylation (sugar attachment), so as to prevent glycosylation at that site(s). The position of such genetic deglycosylation is important and should be between the C terminus of gp120 and the Cys at the N-terminal side of the cysteine loop containing the hyper-variable region 3 (V3) (this Cys is generally positioned about at residue 296, counting from the N-terminus of gp120). The mutant glycoprotein should be deglycosylated such that the total molecular mass of the mutant gp120 component is less than 90% (more preferably less than 75%) of the corresponding fully glycosylated wild type gp120 component to maximize a useful immune response.

REFERENCES:
Bolmstedt, et al, J of Gen Virology, 72:1269-1277, 1991.
Woan-Ruoh, et al, Final Program and Abstracts, 6th International Conference on Aids, San Francisco, CA 3:S.A.8, 1990.
Feizi, et al, Glycobiology 1:17-23, 1990.
Cohen, et al, J of Acquired Immune Deficiency Syndromes, 3:11-18, 1990.
Syu, et al, PNAS, 87:3695-3699, 1990.
Aldovini, et al, J of Virology, 64:1920-1926, 1990.
Leonard, et al, The J of Biol Chem, 265:10373-10382, 1990.
Kozarsky, et al, J of Acquired Immune Deficiency Syndromes, 2:163-169, 1989.
Cohen, et al, Nature, 334:532-534, 1988.
Willey, et al, J of Virology, 62:139-147, 1988.
Chou, et al, The J of Infectious Disease, 157:805-811, 1988.
Geyer, et al, The J of Bio Chem, 263:11760-11767, 1988.
Curran, et al, Science, 239:610-616, 1988.
Mizuochi, et al, Biochem J, 254:599-603, 1988.
Lasky, et al, Cell, 50:975-985, 1987.
Matthews, et al, PNAS, 84:5424-5428, 1987.
Pyle, et al, Aids Research and Human Retroviruses, 3:387-400, 1987.
Lasky, et al, Science, 233:209-212, 1986.
McDougal, et al, Science, 231:382-385, 1986.
Cullen, et al, Cell, 46:973-982, 1986.
Robey, et al, PNAS, 83:7023-7027, 1986.
Veronese, et al, Science, 229:1402-1404, 1985.
Robey, et al, Science, 228:593-595, 1985.
Klatzmann, et al, Nature, 321:767-768, 1984.
Dalgleish, et al, Nature, 312:763-767, 1984.
Allan, et al, Science 228:1091-1094, 1985.
Botarelli et al., "N-glycosylation of HIV-gp120 may constrain recognition by T lymphocytes", J. Immunol., 147(9):3128-32 (1991).
Lee et al., "Non-random Distribution of GP 120 N-linked Glycosylation Sites Critical for HIV-1 Infectivity", AIDS Research and Human Retroviruses, 8(5):917 (1992).
Lee et al., "Nonrandom distribution of gp120 N-linked Glycosylation Sites Important for Infectivity of Human Immunodeficiency Virus Type 1", PNAS USA, 89(6):2213-17 (1992).
Dirckx et al.; Mutation of conserved n-glycosylation . . . ; Vir. Res.; vol. 18(1); pp. 9-20, Dec. 1990.
Bolmstedt et al.; Effects of mutations in glycosylation sites . . . ; J. Gen. Vir.; vol. 72; pp. 1269-1277, Jun. 1991.
Lee, et al, 1990, "Role of N-linked Oligosaccharides of HIV-1 . . . " Abstract No. S.A.8, 6.sup.th International Conference on AIDS, Jun. 24, 1990.
Davis, et al., 1990, "Glycosylation Governs the Binding of . . . " J. of General Virology 71:2889-2898.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Selectively deglycosylated human immunodeficiency virus type 1 e does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Selectively deglycosylated human immunodeficiency virus type 1 e, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Selectively deglycosylated human immunodeficiency virus type 1 e will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2003743

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.